Effect of low level laser therapy in a model of pulmonary idiopathic fibrosis

Rigonato‐Oliveira, Nicole Cristine; Brito, Auriléia Aparecida de; Moraes, Gabriel; Soares, Clariana; Aquino‐Junior, Jefferson Comin Jonco; Vitoretti, Luana Beatriz; Vieira, Rodolfo de Paula; Ligeiro-Oliveira, Ana Paula

doi:10.1183/13993003.congress-2015.pa945

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a model of acute lung injury, LLLT reduced DNA fragmentation and apoptotic pathways via increased B-cell-lymphoma-2 (Bcl-2), the key regulator of the intrinsic or mitochondrial pathway for apoptosis, in alveolar epithelial cells while promoting DNA fragmentation in inflammatory cells [37]. In pulmonary idiopathic fibrosis, LLLT inhibits pro-inflammatory cytokines and increases expression of proliferating cell nuclear antigen [38], attenuates airway remodeling by balancing pro-and anti-inflammatory cytokines in lung tissue, and inhibiting fibroblast secretion of the pro-fibrotic cytokines [36].…”

Section: The Effects Of Lllt On Pulmonary Inflammationmentioning

confidence: 99%

“…LLLT attenuates cytokine storm at multiple levels and reduces the major inflammatory metabolites such as IL-6 and TNF-α. IL-6 antagonists are being investigated for treating COVID-19 but LLLT reduces the production of IL-6, as well as other chemokines and metabolites [26][27][28][29][30][31][32][33][34][35][36][37][38][39]41]. • There are US FDA and Health Canada approved laser machines for pain management, lymphedema after breast cancer surgery, and cellulite treatments that can be used and set to treat lung inflammation.…”

Section: The Effects Of Sars-cov-2 On Alveolar Cell and Cytokine Stormmentioning

confidence: 99%

See 1 more Smart Citation

Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19

Mokmeli¹,

Vetrici

2020

Can J Respir Ther

View full text Add to dashboard Cite

The global pandemic COVID-19 is a contagious disease and its mortality rates ranging from 1% to 5% are likely due to acute respiratory distress syndrome (ARDS), and cytokine storm. A significant proportion of patients who require intubation succumb to the disease, despite the availability of ventilators and the best treatment practices. Researchers worldwide are in search of anti-inflammatory medicines in the hope of finding a cure for COVID-19. Low-level laser therapy (LLLT) has strong, anti-inflammatory effects confirmed by meta-analyses, and it may be therapeutic to ARDS. LLLT has been used for pain management, wound healing, and other health conditions by physicians, physiotherapists, and nurses worldwide for decades. In addition, it has been used in veterinary medicine for respiratory tract disease such as pneumonia. Laser light with low-power intensity is applied to the surface of the skin to produce local and systemic effects. Based on the clinical experience, peer-reviewed studies, and solid laboratory data in experimental animal models, LLLT attenuates cytokine storm at multiple levels and reduces the major inflammatory metabolites. LLLT is a safe, effective, low-cost modality without any side-effects that may be combined with conventional treatment of ARDS. We summarize the effects of LLLT on pulmonary inflammation and we provide a protocol for augmenting medical treatment in COVID-19 patients. LLLT combined with conventional medical therapy has the potential to prevent the progression of COVID-19, minimize the length of time needed on a ventilator, enhance the healing process, and shorten recovery time.

show abstract

Section: The Effects Of Lllt On Pulmonary Inflammationmentioning

confidence: 99%